◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › J › JAZZ

Jazz Pharmaceuticals PLC (JAZZ) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Jazz Pharmaceuticals PLC (JAZZ) operates in the BIOTECHNOLOGY industry and is headquartered in Dublin, Ireland with about 2,890 employees. Its market capitalization is roughly $16 billion. In the fiscal year ended 2025-12-31, JAZZ reported $4.3B in revenue and ($356M) in net income.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

Interactive charts & full statements → Open the JAZZ valuation workbench →

JAZZ Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.6B	$4.3B	$4.1B	$3.8B	$3.7B	$3.1B	$2.4B	$2.2B	$1.9B	$1.6B	$1.5B	$1.3B	$1.2B	$872M	$586M	$272M	$174M	$128M	$68M	$65M	$45M
Gross Profit	$3.9B	$3.8B	$3.6B	$3.4B	$3.1B	$2.7B	$2.2B	$2.0B	$1.8B	$1.5B	$1.4B	$1.2B	$1.1B	$770M	$508M	$258M	$160M	$119M	$54M	$56M	$38M
Gross Margin %	84.7%	88.2%	89.0%	88.6%	85.2%	85.8%	93.7%	94.1%	93.6%	93.2%	92.9%	92.3%	90.0%	88.3%	86.6%	94.9%	92.2%	92.5%	79.4%	86.4%	84.5%
Operating Income (EBIT)	—	$224M	$717M	$579M	($66M)	$170M	$378M	$532M	$615M	$529M	$592M	$508M	$196M	$340M	$198M	$128M	$58M	$16M	($170M)	($139M)	($78M)
Operating Margin %	—	5.3%	17.6%	15.1%	-1.8%	5.5%	16.0%	24.6%	32.5%	32.7%	39.8%	38.4%	16.7%	39.0%	33.8%	46.9%	33.2%	12.4%	-252.3%	-212.5%	-174.0%
Net Income	$940M	($356M)	$560M	$415M	($224M)	($329M)	$239M	$523M	$447M	$488M	$397M	$330M	$58M	$216M	$289M	$125M	$33M	($7M)	($184M)	($139M)	($59M)
Net Margin %	20.4%	-8.3%	13.8%	10.8%	-6.1%	-10.6%	10.1%	24.2%	23.6%	30.1%	26.7%	24.9%	5.0%	24.8%	49.2%	45.9%	18.9%	-5.3%	-273.0%	-212.6%	-132.4%
EBITDA	—	$108M	$1.5B	$1.4B	$1.5B	$1.0B	$1.0B	$1.0B	$933M	$779M	$754M	$666M	$584M	$454M	$310M	$134M	$54M	$25M	($126M)	($128M)	($68M)
Earnings Per Share (EPS)	$14.63	$-5.84	$8.49	$5.76	$-3.58	$-5.51	$4.22	$9.09	$7.30	$7.96	$6.41	$5.23	$0.93	$3.51	$4.79	$2.67	$0.83	$-0.23	$-7.19	$-10.04	$-4.41
Shares Outstanding (M)	—	61M	66M	72M	63M	60M	57M	58M	61M	61M	62M	63M	63M	62M	60M	47M	39M	30M	26M	14M	13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JAZZ Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.2B	$1.1B	$1.2B	$1.1B	$1.0B	$898M	$1.1B	$1.1B	$1.0B
Gross Profit	$1.1B	$762M	$1.2B	$868M	$929M	$793M	$959M	$943M	$914M
Gross Margin %	90.4%	71.3%	97.9%	77.1%	88.9%	88.3%	88.2%	89.4%	89.3%
Operating Income (EBIT)	—	$214M	$909M	$58M	($686M)	($56M)	$191M	$260M	$199M
Operating Margin %	—	20.0%	75.9%	5.1%	-65.6%	-6.2%	17.5%	24.7%	19.5%
Net Income	$193M	$293M	$203M	$251M	($718M)	($93M)	$191M	$215M	$169M
Net Margin %	16.0%	27.4%	17.0%	22.3%	-68.7%	-10.3%	17.6%	20.4%	16.5%
EBITDA	—	$544M	$279M	$236M	($514M)	$139M	$397M	$424M	$363M
Earnings Per Share (EPS)	$2.78	$4.43	$3.34	$4.08	$-11.74	$-1.52	$3.11	$3.40	$2.42
Shares Outstanding (M)	—	66M	61M	62M	61M	61M	62M	63M	70M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JAZZ Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$1.7B	$1.4B	$1.4B	$1.1B	$1.3B	$779M	$900M	$776M	$799M	$693M	$591M	$532M	$406M	$284M	$250M	$152M	$59M	($16M)	($130M)	($81M)	($57M)
Capital Expenditures (CapEx)	$273M	$210M	$48M	$24M	$498M	$46M	$379M	$182M	$131M	$114M	$182M	$36M	$239M	$11M	$22M	$6M	$5M	$6M	$29M	$3M	$2M
Free Cash Flow (FCF)	$1.4B	$1.1B	$1.3B	$1.1B	$774M	$733M	$520M	$594M	$667M	$579M	$409M	$496M	$167M	$272M	$227M	$146M	$54M	($22M)	($159M)	($84M)	($59M)
FCF Margin %	30.1%	26.9%	33.1%	27.9%	21.1%	23.7%	22.0%	27.5%	35.3%	35.8%	27.5%	37.4%	14.2%	31.2%	38.8%	53.5%	31.1%	-17.1%	-235.5%	-129.0%	-131.6%
Dividends Paid	—	—	—	—	$98M	$100M	$100M	$58M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	$6M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JAZZ Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$416M	$408M	$363M	$475M	$89M	$430M	$399M	$399M	$331M
Capital Expenditures (CapEx)	$172M	$20M	$66M	$15M	$12M	$39M	$13M	$11M	$7M
Free Cash Flow (FCF)	$243M	$388M	$297M	$459M	$77M	$391M	$385M	$388M	$324M
FCF Margin %	20.1%	36.4%	24.8%	40.8%	7.3%	43.5%	35.4%	36.8%	31.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JAZZ Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$11.1B	$11.7B	$12.0B	$11.4B	$10.8B	$12.3B	$6.5B	$5.5B	$5.2B	$5.1B	$4.8B	$3.4B	$3.3B	$2.2B	$2.0B	$254M	$136M	$107M	$117M	$208M	$215M
Cash & Cash Equivalents	$1.6B	$1.4B	$2.4B	$1.5B	$881M	$591M	$1.1B	$637M	$310M	$386M	$366M	$989M	$684M	$637M	$387M	$82M	$45M	$16M	$25M	$103M	$79M
Total Liabilities	$6.3B	$7.3B	$7.9B	$7.7B	$7.8B	$8.3B	$2.9B	$2.4B	$2.4B	$2.4B	$2.9B	$1.8B	$2.0B	$943M	$845M	$61M	$105M	$180M	$210M	$153M	$391M
Total Debt (Short + Long-Term)	$4.4B	$5.4B	$6.1B	$5.7B	$5.7B	$6.1B	$2.1B	$1.6B	$1.6B	$1.6B	$2.0B	$1.2B	$1.3B	$550M	$457M	$39M	$48M	$124M	$122M	$79M	$76M
Total Shareholders' Equity	$4.8B	$4.3B	$4.1B	$3.7B	$3.1B	$4.0B	$3.7B	$3.1B	$2.8B	$2.7B	$1.9B	$1.6B	$1.4B	$1.3B	$1.1B	$193M	$31M	($73M)	($93M)	$55M	($176M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JAZZ viewer.

JAZZ Metric Deep Dives

Other Companies in BIOTECHNOLOGY

ROIV · Roivant Sciences Ltd — $29 billion
INSM · Insmed Inc — $26 billion
BNTX · BioNTech SE — $24 billion
GMAB · Genmab AS — $21 billion
ASND · Ascendis Pharma AS — $16 billion
EXEL · Exelixis Inc — $14 billion
SMMT · Summit Therapeutics PLC — $14 billion
BBIO · BridgeBio Pharma Inc — $13 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← JAYSREETEA All “J” companies JBBB →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.